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Background: Though several drugs have been tested, the choice of the ideal steroid-
sparing agent in steroid-dependent asthmatic patients remains unclear. Our
objective was to evaluate the efficacy and tolerance of methotrexate in low weekly
doses in order to decrease chronic oral steroid requirements in asthmatic patients.
Methods: Design: double blind randomized placebo-controlled study. Setting: The
study was performed in a 760-bed teaching hospital. Patients: 46 steroid-dependent
asthmatic patients were randomized. Interventions: Patients received 10mg of
methotrexate or placebo once weekly for a year. The 6-methylprednisolone was
progressively tapered (2mg/day every two weeks) until FEV1 diminished by 5% or
more; 6-methylprednisolone was then increased until the previous FEV1 was
reached, and the procedure was repeated throughout follow-up.
Measurements: Blood and urine analyses and bone densitometry were performed at
entry and at the end of the study. Pulmonary function was tested monthly during the
first three months and then every three months until the end.Elsevier Ltd. All rights reserv
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R. Comet et al.412Results: Thirty-nine patients were evaluated at interim analysis. A 54.8% decrease
(9.574.9mg/day) in 6-methylprednisolone dose was observed in the methotrexate
group and a 4.4% decrease (0.577.2mg/day) in the placebo group (Po0:001). There
was no significant decrease of FEV1 in either group. No changes in bone metabolism
were observed except for a non-statistically significant increase in osteocalcin levels
in the treated group compared to a decrease in the placebo group. Toxicity was mild.
Conclusions: (1) Methotrexate is an effective steroid-sparing agent. (2) A dosage
lower than the one recommended in the literature is effective. (3) Tolerance is good.
(4) No benefit or detrimental effects in bone metabolism were observed after one
year.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The incidence and mortality of asthma have
increased over the years. In our geographical
setting, asthma affects over 3.3% of the popula-
tion.1 Fewer than 1% are steroid-dependent, but
these patients consume most of the time and
resources at asthma units.
Once the key role of inflammation in the
pathogenesis of the disease was established, treat-
ment efforts have focused on anti-inflammatory
drugs. The consensus documents of the various
professional societies2–5 all support a stepwise
therapeutic approach. These documents advocate
treatment with oral corticosteroids for severe
persistent asthmatic patients already receiving
high doses of long-term beta-agonists and inhaled
steroids. The side-effect profile of steroids when
administered over long periods or at high doses is
well known. This is why over the last 50 years many
steroid-sparing drugs have been assessed, but as
yet no ideal candidate has been found.
Among the drugs evaluated, methotrexate,
which has shown undoubted benefits in other
diseases such as psoriasis, rheumatoid arthritis
and ulcerative colitis, is the immunosuppressor
which seems to offer the most benefits to steroid-
dependent asthmatic patients.
Since Mullarkey et al.6 published the first
study suggesting a possible role of methotrexate
in asthma in 1986, other studies have sought
to confirm this hypothesis. To date, however,
no firm conclusion has been reached on whether
or not methotrexate can be considered an
alternative or adjuvant drug to oral steroids in
asthma.
Almost 10 years ago we started treating steroid-
dependent asthmatic patients with a low (10mg
PO) weekly dose of methotrexate. In two open
studies,7,8 we observed a 50% decrease in steroid
dose requirements. In the second of these studies,
we also observed that methotrexate was well
tolerated during a 12-month follow-up.In the light of the results published in the
literature and our positive preliminary experi-
ences, we designed the present study to test the
hypothesis that methotrexate is a clinically useful
drug for the treatment of steroid-dependent asth-
matic patients. Our objective was therefore to
evaluate the long-term efficacy of methotrexate at
low weekly doses in decreasing the dose of oral
steroids, its tolerance, and the potential beneficial
effect of the steroid-dose decrease on bone
metabolism.Population and methods
Population
The study was performed at the Corporacio´ Parc
Taulı´ (CPT) (Sabadell/Barcelona) in Catalonia,
Spain, a 760-bed teaching hospital. Patients were
enrolled by the treating physician according to the
inclusion/exclusion criteria listed below, after
informed consent was signed. The study lasted
from May 1995 to June 2003.
Inclusion criteria
Age 18 years or more with bronchial asthma;
steroid-dependence, defined as a requirement of
at least 7.5mg/day of prednisolone or 6mg/day of
6-methylprednisolone to maintain a forced expira-
tory volume in the first second (FEV1)X70% during a
period of one year or more; failure in full-tapering
of corticosteroids for at least three months.
Exclusion criteria
Renal disease (serum creatinine level X133 mmol/
L); previous neoplasm; long-term insulin-depen-
dent diabetes mellitus; morbid obesity; alcoholism
or history of chronic liver disease or high liver
enzyme levels; peptic ulcer disease; previous or
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tial lung disease; diffusing capacity for carbon
monoxide/alveolar volume (KCO)o70%; AIDS; he-
moglobin level below 100 g/L; white-cell count
below 3.5 109/L; platelet count below 150 109/
L; pregnancy, and patients requiring continued
treatment with tubular secretion inhibitors (peni-
cillin, sulphonamide, acetylsalicylic acid).
Sample size was calculated to ensure a power of
X80% for detecting a decrease between 10% and
50% in the daily steroid dose with a ¼ 0:05. Forty-
eight patients were required, 24 in each branch of
treatment (methotrexate or placebo).
Methods
Study design
Unicenter, randomized, parallel, double-blind, pla-
cebo-controlled trial. The study comprised three
stages.
Stabilization period
Minimal length of 3 months. Patients were treated
following the recommendations of the Interna-
tional Consensus Report on Diagnosis and Treat-
ment of Asthma.2 Steroid doses were progressively
tapered (2mg/day of 6-methylprednisolone every 2
weeks) until a decrease of X5% in the FEV1 was
observed. Steroid dose was then increased to the
previous level and the process was repeated again.
The third time the steroid decrease failed, we
considered that the minimum required steroid
dosage had been reached. During this period, the
rheumatologist ruled out any relevant cause that
could influence bone metabolism (smoking and
alcohol intake, thyroid dysfunction, diabetes,
gastrectomy, hypogonadism, hypercorticism) and
instructed patients to ensure a minimum calcium
intake in their diet of 1500mg (adding calcium pills
if needed) until the end of the follow-up. No drugs
influencing calcium metabolism were adminis-
tered.
Run in period
A 4-week period before randomization and after
the patient had agreed to participate in the trial
and given informed consent.
Treatment period
Patients were randomized to receive a capsule
containing methotrexate (10mg) or placebo (mi-
cro-crystalline cellulose) once a week, for a 12-
month period. The 6-methylprednisolone was pro-
gressively tapered (2mg/day every 2 weeks), until
FEV1 diminished by X5%. It was then increaseduntil the previous FEV1 was reached, and the
procedure was repeated throughout the follow-
up. A computer-generated randomization list was
drawn up by the pharmacist who also allocated
patients to each group on entry. Each patient
collected the treatment directly from the phar-
macy department. The drug and the placebo were
given in identical numbered containers. All study
personnel and participants were blinded to treat-
ment assignment for the duration of the study. Only
the pharmacist, the data collector and the study
statisticians knew the patient’s code.
Outcomes
The primary measured outcome of efficacy was the
decrease in oral steroid dose. Secondary outcomes
were the changes in the FEV1 and bone metabolism
benefit. The primary security outcome was to
estimate the incidence of the side-effects of the
drug.
Instrumentalization
Laboratory tests
At the beginning and end of the study, we
performed in each patient: blood analysis (includ-
ing hemogram, total lymphocytes and CD4 and CD8
counts, liver and renal function tests, glucose,
thyroid function tests, IgG, IgA, IgE, IgM, IgD, IgG
subclasses, calcium, phosphorous and osteocalcin);
24-h urinalysis (calciuria); bone reabsorption index
according to Nordin criteria (calcium/creatini-
ne—mg Ca/mg creatinine; normal values
0.012–0.167—and hydroxyproline/creatinine ratios
in a 2 h urine sample after a night fast—nmol
hydroxyproline/mg creatinine; normal values:
72–159).9 Four days before performing these
analyses, patients were instructed to avoid jelly
intake. Monthly during the first trimester and then
every 3 months until the end, a blood analysis was
performed. Two-hour and 24-h urinalyses were
performed at the 6-month control and at the end
of the study.
Osteocalcin was measured by radioimmunoassay
(CIS, Gif-Suryvet Cedex, France) (normal values:
male: 1.2–18 ng/mL; pre and post-menopausal
females: 1.2–12.8 and 4.9–18 ng/mL, respectively).
Immunoglobulin levels were determined by nephe-
lometry and IgG subclasses (IgG1, IgG2, IgG3, IgG4)
were measured by radiated immunodiffusion.
Pulmonary function testings (PFTs)
Forced spirometry, pulmonary volumes and CO
transfer capacity measurements were performed
on each patient at the beginning and end of the
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during the first trimester and then every 3 months
until the end. PFTs were carried out in our
pulmonary function laboratory, which is equipped
with automated PFT equipment (MedGraphics sys-
tem 1070 Series 2E/1085) for pulmonary volume,
diffusion and spirometric test. Reference values for
the Mediterranean population were used.10 Arterial
blood gases (ABG) were measured at the beginning
and end of the study (Radiometer ABL 500).
Imaging tests
At entry, a high-resolution chest CT scan (HRCTS)
and an abdominal ultrasonography were performed
in our Radiology Department (Asteion, Toshiba). A
chest X-ray was performed every 6 months. A bone
densitometry was performed at entry and at the
end of the study in a private center (CETIR-
Medicina Nuclear, Barcelona), with a DPX (Lunar
Corporation) team, using dual energy X-ray absorp-
tiometry (DEXA). Measurements were performed in
femoral neck, Ward triangle and lumbar spine
(L2–L4) and results expressed in g/cm
2 and T-score.
The T-score represents the number of standard
deviations (SDs) from the normal young adult mean
bone density values. According to the T-score,
osteoporosis was considered to be present when
the score was below 2.5 SDs; score values between
1 and 2.5 SDs are considered as showing osteo-
penia.
The study was approved by the Ethics Committee
of the hospital and patients were asked to give
informed consent. They were also given a descrip-
tion of the potential side-effects of the drug.
Statistical methods
Statistical package for the social sciences (SPSS)
was used for the data entry and analysis. The
results are given as mean (SD) values. StatisticalTable 1 Characteristics of the population at entry.
Methotrexate
Sex (male/female) 6/18
Age (years) 56712
FEV1 (L)
 1.6270.63
FEV1 (%) 64.42718.15
FEV1/FVC (%)
y 56.92710.97
pH 7.4370.02
PaO2 (mm Hg)
z 83.2711.1
PaCO2 (mm Hg)
y 37.974.3
FEV1: forced expiratory volume in the first second.
yFVC: forced vital capacity.
zPaO2: arterial oxygen pressure on room air.
yPaCO2: arterial carbon dioxide.comparisons between groups were performed using
the Student’s two-tailed unpaired t-test. For
intragroup comparisons, the Student’s t-test for
paired data was used. An interim analysis was
scheduled to be performed when X75% of the
patients had been included. The O’Brien–Fleming
method was applied; with this method, the mini-
mum P-value necessary to consider statistically
significant differences was Po0:023 in the interim
analysis or Po0:43 at the end.Results
Description of the population
Forty-six patients agreed to enter the study. The
mean age was 57.3712.3 years. Thirty-two pa-
tients (69.6%) were female and 14 male (30.4%).
PFTs of the whole population showed a mild
obstructive pattern (FEV1 1.5570.61 L;
62.83719.17%). ABG values were normal (Table
1). Laboratory tests showed normal values. After
randomization, there were no differences between
the groups in terms of age, sex, laboratory results,
ABG and PFTs (Table 1).
The HRCTS performed at the beginning of the
trial showed bronchiectasis in 12 patients, 6 in each
group. The chest X-ray performed at the end of the
follow-up showed no changes with regard to those
at entry.
The bone densitometry performed at entry
showed clear osteopenia, with lower bone mineral
density (BMD) (T-score) in Ward triangle and
femoral neck in the methotrexate group
(Table 2). No intragroup or intergroup differences
were found during follow-up.Placebo P
8/14 NS
58.6712.8 NS
1.4870.59 NS
61.09720.52 NS
54.95714.95 NS
7.4370.02 NS
8478.8 NS
39.273.9 NS
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Table 2 Densitometric values at entry (T0) and follow-up (T12).
T0 T12
Methotrexate Placebo P Methotrexate Placebo P
Femoral neck (g/cm2) 0.7970.14 0.8470.14 NS 0.7470.14 0.8370.13 NS
Femoral neck (T) 1.8271.08 1.3471.01 NS 2.2171.16 1.3970.99 NS
Ward triangle (g/cm2) 0.6470.14 0.6970.16 NS 0.6070.15 0.6770.16 NS
Ward triangle (T) 2.2271.03 1.7771.22 NS 2.4771.25 1.9671.15 NS
L2–4 (g/cm
2)y 0.9570.19 1.0470.22 NS 0.9370.21 1.0270.25 NS
L2–4 (T) 2.2171.56 1.4571.89 NS 2.3371.66 1.5872.06 NS
T-score: represents the number of SDs from the normal sex-adjusted young adult mean bone mineral density values.
yL: lumbar vertebra.
PlaceboMethotrexate
Si
x-
m
et
hy
l-
pr
ed
ni
so
lo
ne
 m
g/
da
y
50
40
30
20
10
0
Figure 1 The 6-methylprednisolone dose (in mg/day) at
randomization of both groups (methotrexate and place-
bo). The median value of 6-methylprednisolone dose is
12mg/day for both groups and no statistical differences
were found at the beginning of the study. Two outliers in
the methotrexate were found.
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10.378.7 months (range: 3–36 months) and the
mean 6-methylprednisolone dose at the beginning
of this period was 20.9712.4mg/day. No differ-
ences between groups were found after randomiza-
tion in terms of length of the stabilization period or
steroid dose at the beginning. The mean daily 6-
methylprednisolone dose administered at the time
of randomization was: 15.278.9mg/day for the
whole population; 17.3710.1mg/day for the meth-
otrexate group; 12.876.8mg/day for the placebo
group (P ¼ NS). The median value was 12mg/day
for both groups (Fig. 1).Follow-up and side-effects
Forty-six patients (24 from the methotrexate group
and 22 from the placebo group) were included at
the time of the interim analysis. Seven patients
were excluded during the trial: two patients from
the placebo group died of unrelated causes; onepatient from each group abandoned the study due
to subjective clinical improvement; one patient
from the placebo group dropped out because of
unspecific symptoms; two patients from the meth-
otrexate group dropped out due to side-effects:
one case of diarrhoea and the other of bronchos-
pasm (this patient did not notify the investigators
and was thus exposed to methotrexate twice,
fulfilling the Karch and Lassagna criteria11 for the
identification of adverse drug reactions). So, in
total 39 patients were analyzed, 21 from the
methotrexate group and 18 from the placebo
group.Corticosteroid reduction
A reduction in the steroid-dose was observed in
both groups at the first control. This reduction was
significantly higher in the methotrexate group. At
the end of the study, 6-methylprednisolone dose
decreased by 54.8% in the methotrexate group
(from 17.3710.15 to 7.875.1mg/day) but only by
4.4% (from 12.876.8 to 12.3670.4mg/day)
(Po0:001) in the placebo group. A progressive
decrease in the corticosteroid dose was observed
during the first 9 months in the treated group
(Fig. 2).Pulmonary function testing
Mean FEV1 showed a slight, non-significant de-
crease in both groups: from 1.62 to 1.59 L/s in the
methotrexate group and from 1.48 to 1.39 L/s in
the placebo group. The other parameters of the
complete PFTs and ABG remained stable and
showed no differences between groups.
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Figure 3 The figure shows the osteocalcin values and
tendencies in both groups. However, no statistically
significant differences were observed during the one-
year follow-up.
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Figure 2 This figure represents the progressive 6-
methylprednisolone dose (in mg/day) decrease. Each
point represents the difference of the mean dose of 6-
methylprednisolone at the moment of the follow-up
compared to the beginning. Since the dose of 6-
methylprednisolone decreases in both groups, the values
are plotted in the negative part of the Y-axis. Note that in
the methotrexate group the difference did not stabilize
until the ninth month.
R. Comet et al.416Laboratory results
No changes were observed during follow-up in
hemogram, liver and renal function, humoral or
cellular immunity.Bone metabolism
After 12 months of treatment, no intergroup or
intragroup differences were observed (Table 2). No
benefit was found in any of the parameters
analyzed (bone densitometry, blood or urine ana-
lysis) except for a non-statistically significant trend
of osteocalcin levels to increase in the methotrex-
ate group and to decrease in the placebo group
(Fig. 3).Discussion
Since the International Consensus Report on Diag-
nosis and Treatment of Asthma2 was published in
1992, many other guides for asthma treatment
have been proposed3–5 but none of them have
examined therapeutic alternatives to oral steroids
in chronic asthma. Since morbidity due to pro-
longed oral steroid treatment is well established,
we decided to conduct a study which, in the light of
our experience, might help to manage this popula-
tion of asthmatics.
In the literature many drugs12–15 have been tried
as sparing steroid agents. In the majority, the
authors have failed to demonstrate the beneficial
effects of the drugs. Apart from methotrexate only
gold salts16,17 and cyclosporin18,19 have been
considered effective, although their possible side-
effects have limited their use.
Methotrexate has been used for more than 20
years to treat inflammatory diseases such as
rheumatoid arthritis and psoriasis. In 1986, Michael
Mullarkey observed for the first time the potential
benefits of this drug in bronchial asthma.6 Since
then, several studies have been published, but
many of them have had a small sample size, short
follow-up period, inappropriate design or high
doses of methotrexate. The results were contra-
dictory until the double-blind placebo-controlled
study published by Shiner and co-workers showed
the benefits of the drug.20 Unfortunately, since
then, several other controversial papers have been
published which have not helped to clarify the
situation. Moreover, there is no agreement on the
dose at which the drug should be administered.
Some authors advocate an oral weekly dose
between 15 and 30mg,21–23 but others have used
50mg per week by intramuscular injection.24 The
importance of establishing the therapeutic dose is
crucial, since a lower dose would help to diminish
the incidence of side-effects.
Based on our own experience,7,8 we decided to
design a double-blind placebo-controlled study
with the clear aim of determining whether metho-
trexate has a clinically relevant steroid-sparing
effect. The purpose of the study was not to improve
the PFTs. The design of the study was very
demanding, since we established a very long
stabilization period (the longest in the literature),
a run-in period (the importance of this section has
been highlighted by the Cochrane review15) and the
longest treatment period of any trial published to
date (covering the four seasons of the year). The
trial was carefully designed to calculate the
number of patients to be treated in order to obtain
the expected results and finally, for ethical
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therapeutic section of the protocol, we established
that patients would receive 800 mg of budesonide
daily. It could be argued that this dose is low;
indeed, this may well be the case in patients with
an eosinophilic infiltration. If the inflammatory
cells are mainly neutrophils, an increase in the dose
of inhaled steroids would probably not improve
patients’ PFTs. We decided on this dose since it is
beneficial regardless of the sort of inflammatory
cells involved in asthma and, since it is well
tolerated, we would be reducing the probabilities
of finding major differences in inhaled steroid dose
between groups. Patients were informed of this
decision before entering the study.
Our results clearly show that methotrexate has a
steroid-sparing effect. The decrease in the steroid
dose obtained was 54.8%. As important as the
percentage of dose is the number of milligrams of
6-methylprednisolone that patients would avoid
taking. When the results are shown in mg, many
studies fail to demonstrate that methotrexate is a
clinically relevant option. In our series, methotrex-
ate reduced the daily needs of 6-methylpredniso-
lone by 9.5mg/day (from 17.3 to 7.8mg/day). The
clinical relevance of this point is stressed in the
literature, since significant trabecular bone loss
develops with prednisone doses X7.5mg/day in
most patients25,26 and the reduction of bone
mineral density correlates with daily dose of
prednisone taken.27 In their meta-analysis, Aaron
et al.28 and Marin29 showed that studies with a
more demanding design showed a greater bene-
ficial effect of methotrexate. We believe that our
results provide the clearest evidence in favor of
methotrexate since we fulfilled all the criteria
considered relevant by Marin.29
We stress that the decrease in steroid started
quite late, between 4 and 12 weeks after initiating
the treatment, and lasted several months
(9 months in some cases). This is probably due
to the low dose of methotrexate we used and
because the mechanism of the therapeutic
effect of the drug effect is slow. As a result,
one should not conclude that the drug is not
effective until several months after the beginning
of treatment.
We were not able to show a statistically
significant beneficial effect on bone metabolism
due to the fact that in both arms of the study
steroid doses were not very high and the maximum
effect of methotrexate was not reached until the
ninth month of treatment. The fact that the largest
difference in steroid dose between the groups
occurred in the last three months may contribute to
explaining the absence of benefits in the re-absorption parameters. The re-absorption para-
meters we used were the ones considered most
representative at the moment we started the
study. Since then, they have been replaced by
other more sensitive biochemical markers such as
pyridinoline, deoxypyridinoline and carboxy- and
amino-telopeptide levels30 which are more reliable
and less influenced by diet and calcium intake.
Levels of osteocalcin, a specific marker of bone
formation,31 were found to increase at the end of
the follow-up in the treated group and decreased in
the placebo group, thus suggesting that the
impairment of bone formation by steroid treat-
ment32–34 may be partially reversed in the treated
group due to the decrease in steroid dose. How-
ever, the restriction of the follow-up period to one
year, although the longest in the literature, is
probably too short to evidence statistically sig-
nificant differences.
Although high doses of methotrexate—such as
administered in malignancies—have deleterious
effects on bone metabolism, a great many recent
reports state that there are no negative effects on
bone mineral density and bone turnover markers
when low doses are used.34–37 However, combined
treatment with methotrexate and oral prednisone
has been associated with greater bone mineral loss
than corticosteroids alone.38 At least in our study
the beneficial effects of steroid reduction on bone
metabolism did not appear to be impaired by
concomitant methotrexate treatment over a one
year follow-up period.34 Obviously, since one of the
purposes of the study was to evaluate bone
metabolism changes caused by treatment, preven-
tive therapy against osteoporosis was not per-
formed.
Finally, we should stress that the decrease in
steroid dose moved the patients to a lower
treatment level because the international guide-
lines recommend the use of biphosphonates39 only
when daily steroid dose of 6-methylprednisolone is
47.5mg. When it is o7.5mg, calcium and vitamin
D alone seem to prevent bone loss.40
Side-effects were not important. Again this was
probably due to the low dose of methotrexate (only
two patients dropped out due to non-life-threaten-
ing side-effects). We did not find significant
increases in transaminases, and the immunologic
parameters of the patient were not affected. We
conclude that this low weekly dose is safe enough
for routine use.
The most important limitation of the study is that
we did not evaluate whether higher doses of
methotrexate would offer faster benefit for these
patients, since our purpose was to try to find the
lowest useful doses, which would be tolerated the
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trexate dose might help ‘‘non-responders’’.
In conclusion, methotrexate in low weekly doses
proved to be safe and useful as a steroid-sparing
agent. The benefits occur after several months of
treatment (more than three months) and mild
benefits for bone formation can be assumed. Thus,
in the absence of better alternatives, we believe
that a therapeutic trial with methotrexate should
be performed over a period of several months.References
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